The rapid development of angiogenic growth factor therapy for patients with
advanced ischemic heart disease over the last 5 years offers hope of a new
treatment strategy based on generation of new blood supply in the diseased
heart. However, as the field of therapeutic coronary angiogenesis is matur
ing from basic and preclinical investigations to clinical trials, many new
and presently unresolved issues are coming into focus. These include in-dep
th understanding of the biology of angiogenesis, selection of appropriate p
atient populations for clinical trials, choice of therapeutic end points an
d means of their assessment, choice of therapeutic strategy (gene versus pr
otein delivery), route of administration, and the side effect profile. The
present article presents a summary statement of a panel of experts actively
working in the field, convened by the Angiogenesis Foundation and the Angi
ogenesis Research Center during the 72nd meeting of the American Heart Asso
ciation to define and achieve a consensus on the challenges facing developm
ent of therapeutic angiogenesis for coronary disease.